Pocket Naloxone Corp.
Pinova Therapeutics is developing a simple, cost-effective, and ready-to-use Naloxone product with a patented novel dosage form. Their mission is to provide accessible and affordable OTC Naloxone to prevent opioid overdose deaths, removing barriers such as stigma, pharmacist confusion, and high prices. They aim to combat the overdose crisis with innovative solutions and are actively pursuing FDA approval for OTC Naloxone products.
Industries
Nr. of Employees
small (1-50)
Pocket Naloxone Corp.
Patents
Products
Over‑the‑counter nasal swab emergency rescue product (opioid antagonist)
A ready‑to‑use single‑use nasal swab dosage form intended to deliver an opioid antagonist rapidly for emergency opioid overdose reversal; clinical PK data reported higher early systemic exposure compared with some comparator routes.
Personal therapy
Professional personal therapy service offering online and offline sessions with 8 years of experience.
Over‑the‑counter nasal swab emergency rescue product (opioid antagonist)
A ready‑to‑use single‑use nasal swab dosage form intended to deliver an opioid antagonist rapidly for emergency opioid overdose reversal; clinical PK data reported higher early systemic exposure compared with some comparator routes.
Personal therapy
Professional personal therapy service offering online and offline sessions with 8 years of experience.
Services
Design and execution of human factors validation studies and pharmacokinetic clinical studies to assess usability and early systemic exposure of a single‑use nasal swab dosage form.
Development of retail distribution, pricing, and access strategies to enable over‑the‑counter availability of an emergency nasal swab rescue product.
Design and execution of human factors validation studies and pharmacokinetic clinical studies to assess usability and early systemic exposure of a single‑use nasal swab dosage form.
Development of retail distribution, pricing, and access strategies to enable over‑the‑counter availability of an emergency nasal swab rescue product.
Expertise Areas
- Emergency dosage form design (nasal swab formats)
- Intranasal drug delivery and rapid‑absorption formulation
- Clinical pharmacokinetics and PK study execution
- Human factors and usability evaluation for emergency medical products
Key Technologies
- Nasal swab drug delivery
- Intranasal rapid‑absorption formulation
- Clinical pharmacokinetic study methods
- Human factors/usability testing protocols
News & Updates
Human Factors Validation Study demonstrated that adolescents and adults could follow the instructions to correctly administer NaxSwab™ OTC in a simulated emergency environment.
The FDA has encouraged pharmaceutical companies to apply for approval for over-the-counter versions of naloxone to combat the overdose crisis from bootleg fentanyl.
Pharmacokinetic study data in healthy volunteers shows NaxSwab™ OTC has 74% and 1096% higher exposures at 2.5 minutes compared to naloxone HCI 4mg nasal spray and 0.4mg IM naloxone injection.
Guidance on supporting clients dealing with trauma.
Using positive psychology techniques in coaching.
Guided meditation scripts to enhance wellbeing.
Human Factors Validation Study demonstrated that adolescents and adults could follow the instructions to correctly administer NaxSwab™ OTC in a simulated emergency environment.
The FDA has encouraged pharmaceutical companies to apply for approval for over-the-counter versions of naloxone to combat the overdose crisis from bootleg fentanyl.
Pharmacokinetic study data in healthy volunteers shows NaxSwab™ OTC has 74% and 1096% higher exposures at 2.5 minutes compared to naloxone HCI 4mg nasal spray and 0.4mg IM naloxone injection.
Guidance on supporting clients dealing with trauma.
Using positive psychology techniques in coaching.
Guided meditation scripts to enhance wellbeing.